Advances in Plasma Hemostasis

Dear Colleagues,

Although the key plasma proteins involved in hemostasis are known, defining the regulation of each constituent molecular event that leads to clot formation remains an active area of ongoing research. At the genetic level, the increasing availability of genomic data provides clear evidence of protein sequence variation in hemostasis-related plasma proteins, which may explain the variability in protein levels/activity found in the population. At the protein level, protein–protein interactions and post-translational modifications of hemostatic proteins are emerging regulatory mechanisms in physiological and pathological roles. On a temporal scale, the hemostatic system changes and evolves throughout time, with age-related changes in the level/activity of hemostasis plasma proteins likely having an impact on inflammatory and age-related diseases.

An improved understanding of coagulation biology is critical to ensuring optimal prevention, diagnosis, and treatment of thrombotic and hemorrhagic diseases and may provide opportunities to develop novel therapeutic approaches.

This Special Issue aims to collect original and review articles concerning the coagulation anticoagulant systems, and the role of complement in blood coagulation in physiological and pathological contests.

In addition, this Special Issue welcomes work on clinical and laboratory research on hemostasis, physiopathology, and therapy of hemorrhagic and thrombotic diseases, novel cellular and molecular studies, and new developments in the diagnosis, therapy, and prognosis of blood coagulation disorders, as well as novel therapeutic approaches.

We look forward to receiving contributions from all over the world.

Dr. Andrea Caricasole
Dr. Nicole Ziliotto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• coagulation system
• anticoagulant system
• complement system
• blood coagulation disorders
• aging hemostasis
• therapeutics development
• genetic insights
• molecular and biochemical aspects
• post-translational modifications
• inflammation
• neurodegeneration